December 30, 2020
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Laura Crotty
| Re: | Marrone Bio Innovations, Inc. |
| Registration Statement on Form S-3 | |
| Filed on December 11, 2020 | |
| File No. 333-251284 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Marrone Bio Innovations, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of its registration statement on Form S-3 (File No. 333-251284) to 9:00 a.m., Eastern Time, on January 5, 2021, or as soon as practicable thereafter. This letter amends and supersedes the Registrant’s prior letter sent today requesting acceleration on January 4, 2021.
The Registrant requests that it be notified of such effectiveness by contacting Alfredo B. D. Silva, the Company’s counsel at Morrison & Foerster LLP, at (415) 268-6213 or asilva@mofo.com.
| Very truly yours, | ||
| Marrone Bio Innovations, Inc. | ||
| By: | /s/ Linda V. Moore | |
| Name: | Linda Moore | |
| Title: | Executive Vice President, General Counsel and Secretary | |